Effect of tranexamic acid on early postvitrectomy diabetic haemorrhage; a randomised clinical trial.
OBJECTIVE
To evaluate the effect of tranexamic acid on early postvitrectomy haemorrhage in diabetic patients.


METHODS
In a clinical trial, 62 diabetic patients scheduled for vitrectomy were randomly assigned to two groups. The treatment group (32 eyes) received two doses of tranexamic acid (10 mg/kg) shortly before and after the operation intravenously, continued orally for 4 days (20 mg/kg/8 hours). The control group (30 eyes) received no medication. Both media clarity and visual acuity were compared during 4 weeks.


RESULTS
Four weeks after surgery visual acuity was low (< or =1 metre counting fingers) in 21.4%, moderate (>1 metre counting fingers but<20/200) in 14.3%, and good (> or =20/200) in 64.3% of the treated group. Corresponding figures in the control group were 26.1%, 26.1%, and 47.8%, respectively. These differences were of no statistical significance. The ratio of mild to severe vitreous haemorrhage during the first 4 days and after 4 weeks was 79% to 21% and 82% to 18% in the treatment group and 76.7% to 23.3% and 78.3% to 21.7% in the control group respectively, which showed no statistically significant difference.


CONCLUSIONS
Tranexamic acid, with the method of administration in this study, had no effect on reducing early postvitrectomy haemorrhage in diabetic patients.
Ramezani
A R
AR
Ophthalmic Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran.
Ahmadieh
H
H
Ghaseminejad
A K
AK
Yazdani
S
S
Golestan
B
B
D000328:Adult; D000368:Aged; D000933:Antifibrinolytic Agents / Q000627:therapeutic use*; D015986:Confounding Factors, Epidemiologic; D003930:Diabetic Retinopathy / Q000601:surgery*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019990:Perioperative Care / Q000379:methods; D011184:Postoperative Period; D012720:Severity of Illness Index; D014148:Tranexamic Acid / Q000627:therapeutic use*; D014792:Visual Acuity; D014821:Vitrectomy / Q000009:adverse effects*; D014823:Vitreous Hemorrhage / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*
D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid